Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14063106 | 0.88 | MGLL (0.36) | CYP3A4TP53TSHRALDH1A1MGLL | |
| SCHEMBL8734571 | 0.81 | MGLL (0.36) | MGLLALOX5PTGS1PTGS2 | |
| SCHEMBL2257702 | 0.80 | MGLL (0.35) | CYP3A4TP53TSHRALDH1A1MGLL | |
| SCHEMBL15761710 | 0.80 | CYP3A4 (0.37) | CYP3A4TP53TSHRKDM4EALDH1A1 | |
| SCHEMBL131333 | 0.79 | TDP1 (0.38) | CYP3A4TP53TSHRALDH1A1MGLL | |
| SCHEMBL9843341 | 0.78 | MEN1 (0.39) | CYP3A4TP53TSHRALDH1A1MGLL | |
| Water SCHEMBL29048719 | 0.77 | TDP1 (0.37) | CYP3A4TP53TSHRALDH1A1MGLL | |
| SCHEMBL306043 | 0.77 | ALDH1A1 (0.44) | LMNATP53TSHRALDH1A1 | |
| SCHEMBL1774352 | 0.76 | HCAR2 (0.49) | CYP3A4LMNAKDM4EALDH1A1ATM | |
| SCHEMBL10387394 | 0.75 | ALDH1A1 (0.50) | CYP3A4LMNATP53TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888401-B2 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7703907-B2 | Ink composition, inkjet-recording method and printed material | FUJIFILM CORPORATION (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20080033072-A1 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | FUJIFILM CORPORATION (JP) | 2008-02-07 | — | — | US | disclosed |
| US-20060222832-A1 | Ink composition, inkjet-recording method and printed material | FUJI PHOTO FILM CO., LTD. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033072-A1 | Ink composition and inkjet ink, and image-forming method and recorded material using the same, and oxetane compound | OXER1, IPO11, NOXO1 | CYP3A4 1252/4885LMNA 3892/4885TP53 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.